跳至主要内容
临床试验/NCT02781597
NCT02781597已完成3 期

Efficacy of Tranexamic Acid in Controlling Hemoptysis, A Randomized Control Trial

Post Graduate Institute of Medical Education and Research, Chandigarh1 个研究点 分布在 1 个国家目标入组 66 人开始时间: 2011年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
66
试验地点
1
主要终点
Change in severity of hemoptysis

研究概览

简要总结

The purpose of study is to evaluate the efficacy of tranexamic acid in controlling bleeding in patients of hemoptysis and also to evaluate the safety of tranexamic acid.

详细描述

Hemoptysis is a common problem in India due to high incidence of tuberculosis and also due to post tubercular sequale. Hemoptysis is usually managed conservatively in mild to moderate cases and cases of massive hemoptysis are managed with more definitive treatment options like vessel embolization (bronchial/pulmonary artery) and surgery as a last option. Tranexamic acid is a antifibrinolytic used in many surgeries and trauma patients to control bleeding and it has been shown effective and safe. The purpose of the study is to evaluate the efficacy of tranexamic acid in patients with hemoptysis in controlling bleeding.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Acute ongoing hemoptysis
  • Age: 18 years and above

排除标准

  • Pregnant females
  • Females on oral contraceptives
  • Patients on antifibrinolytics
  • Patients with known drug allergy
  • Patients with renal failure
  • Patients requiring intubation during study period
  • Patients with Massive hemoptysis (>600 ml/24 hrs)

研究组 & 干预措施

Tranexamic acid

Active Comparator

All patients will receive basic resuscitative measures and standard treatment like assessment and management of Airway, breathing, circulation, antitussives, and blood products. Patients in group T will receive Inj Tranexamic acid in a loading dose of 1 g over 10 min followed by an infusion of 1 g over 8 h.

干预措施: Tranexamic Acid (Drug)

Placebo

Placebo Comparator

All patients will receive basic resuscitative measures and standard treatment like assessment and management of Airway, breathing, circulation, antitussives, and blood products. Patients will receive 0.9% normal saline instead of Tranexamic acid.

干预措施: Placebo (Drug)

结局指标

主要结局

Change in severity of hemoptysis

时间窗: day1 and day2

Frequency, amount, VAS score Objective assessment using VAS score at admission and at 48 hours.

次要结局

  • Intervention needed(2 days)
  • Blood transfusion needed(2 days)
  • Hospital stay(Through study completion, an average of 1 year)

研究者

发起方
Post Graduate Institute of Medical Education and Research, Chandigarh
申办方类型
Other
责任方
Principal Investigator
主要研究者

Balaji Laxminarayanshetty Bellam

junior resident

Post Graduate Institute of Medical Education and Research, Chandigarh

研究点 (1)

Loading locations...

相似试验